- https://doi.org/10.1182/blood.2025029932
DRiving STandard-of-care CAR T cells in real-world Germany.
Abstract
Translate Article 
Take Notes
Translate Article Take Notes DRiving STandard-of-care CAR T cells in real-world Germany.
ReferencesShowing 10 of 10 papersEffective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Bridging Radiotherapy to Axicabtagene Ciloleucel (axi-cel) Is Associated with Favourable Outcomes for Large B-Cell Lymphoma (LBCL) in Third-Line and Beyond: An Australian Single-Centre Real-World Experience Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Improved outcomes of large B-cell lymphoma patients treated with CD19 CAR T in the UK over time.
101 - 10.1182/bloodadvances.2022009019
- Jun 16, 2023
- Blood Advances
- 32
- 10.1038/s41375-021-01196-3
- Mar 8, 2021
- Leukemia
- 10.1182/blood-2024-209767
- Nov 5, 2024
- Blood
- 12
- 10.1182/bloodadvances.2023011489
- Nov 21, 2023
- Blood Advances
- 10.1182/blood.2024026216
- Apr 8, 2025
- Blood
- 10.1182/blood.2025028330
- Jun 12, 2025
- Blood
- 28
- 10.1182/blood.2024025945
- Oct 9, 2024
- Blood
- 1814
- 10.1056/nejmoa2024850
- Feb 25, 2021
- New England Journal of Medicine
- 1247
- 10.1016/s0140-6736(21)00933-8
- Jun 24, 2021
- The Lancet
- 6
- 10.1111/bjh.19157
- Oct 17, 2023
- British Journal of Haematology
More from: BloodClassic Hodgkin lymphoma with signet ring cell morphology mimicking adenocarcinoma. Molecular clues to venous thromboembolism recurrence. Breaking T-cell tolerance to fight multiple myeloma. Methylation profiling: unmasking CAEBV's lymphoma connection. "Connexin" the dots in hematopoietic stem cell potential. Double trouble for a blurry foe: precision strike on BCL11B. AML biology matters, so should we transplant ASAP? Molecular determinants of thrombosis recurrence risk across venous thromboembolism subtypes. Lampson B, Zakharyan A, Shimony SO, Shi H, Deangelo D. Analysis of avapritinib clinical trial data generates a highly accurate predictive model for advanced systemic mastocytosis versus indolent systemic mastocytosis based on peripheral blood testing. Blood. 2024;144(suppl 1):107. Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy.
- New
- Research Article
- 10.1182/blood.2025029949
- Nov 6, 2025
- Blood
- New
- Front Matter
- 10.1182/blood.2025030460
- Nov 6, 2025
- Blood
- New
- Front Matter
- 10.1182/blood.2025030552
- Nov 6, 2025
- Blood
- New
- Front Matter
- 10.1182/blood.2025030040
- Nov 6, 2025
- Blood
- New
- Front Matter
- 10.1182/blood.2025030225
- Nov 6, 2025
- Blood
- New
- Front Matter
- 10.1182/blood.2025030748
- Nov 6, 2025
- Blood
- New
- Front Matter
- 10.1182/blood.2025030527
- Nov 6, 2025
- Blood
- New
- Research Article
- 10.1182/blood.2024027879
- Nov 6, 2025
- Blood
- New
- Research Article
- 10.1182/blood.2025031471
- Nov 6, 2025
- Blood
- New
- Research Article
- 10.1182/blood.2025028481
- Nov 6, 2025
- Blood
- Ask R Discovery
- Chat PDF
AI summaries and top papers from 250M+ research sources.
What is the difference between bacteria and viruses?
What is the function of the immune system?Can diabetes be passed down from one generation to the next?